NCT03900169

Brief Summary

Famulial hypercolerstremia as risk factor

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 25, 2019

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 2, 2019

Completed
1.6 years until next milestone

Study Start

First participant enrolled

November 1, 2020

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2021

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2021

Completed
Last Updated

June 7, 2021

Status Verified

June 1, 2021

Enrollment Period

9 months

First QC Date

March 25, 2019

Last Update Submit

June 3, 2021

Conditions

Familial Hypercholesterolemia

Outcome Measures

Primary Outcomes (2)

  • Correlation between familial hypercolerstremia and prognosis of patients in PPCI

    Correlation between familial hypercolerstremia and prognosis of patients in PPCI

    One year

  • Correlation between non familial hypercolerstremia and prognosis of patients in PPCI

    Correlation between non familial hypercolerstremia and prognosis of patients in PPCI

    One year

Study Arms (1)

Stemi patient

Stemi patient who underwent Ppci

Genetic: Genetic

Interventions

GeneticGENETIC

Lipid profile

Stemi patient

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Stemi patient

You may qualify if:

  • all patient that underwent Ppci

You may not qualify if:

  • Previous ischemic patient
  • Patient with raised renal chemistry
  • Patient for CABG

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Amira harby

Asyut, Egypt

Location

MeSH Terms

Conditions

Hyperlipoproteinemia Type II

Condition Hierarchy (Ancestors)

Lipid Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesHyperlipoproteinemiasHyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principle investigator

Study Record Dates

First Submitted

March 25, 2019

First Posted

April 2, 2019

Study Start

November 1, 2020

Primary Completion

August 1, 2021

Study Completion

November 1, 2021

Last Updated

June 7, 2021

Record last verified: 2021-06

Locations

EG(1)